Biotech entity
Of the tracked stories, 3 of 4 also mention Eli Lilly, the most common co-covered peer. Each story carries 7.3 original sources on average, compared with 3.6 for the broader beat in this window. The 165-day window averages about 0.2 stories each week.
Last mentioned: Aug 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 4 also mention Eli Lilly, the most common co-covered peer. Each story carries 7.3 original sources on average, compared with 3.6 for the broader beat in this window. The 165-day window averages about 0.2 stories each week. Their average consequence score of 6.5 runs above the beat's 6.1 for that window. The clearest coverage concentration is fda-approval: 2 of 4 stories, with the rest divided among 1 other category. We currently track 4 Biotech stories that mention Zepbound, published between March 13, 2026 and August 24, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 507 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zepbound. Shared-story counts are live from our verified record — not editorial picks.
Medicare GLP-1 Bridge pilot launches
CMS begins covering Wegovy and Zepbound for weight loss under a temporary pilot, offering potential $50 copays for eligible beneficiaries instead of $1,000+ list prices.
Publication of Articles
Two sources publish analyses on reasons to buy Eli Lilly stock, highlighting recent performance and future prospects
Duquesne Family Office initiates RYTM position
In Q2 2026, Stanley Druckenmiller's investment firm discloses a new stake in Rhythm Pharmaceuticals.
FDA expands Imcivree approval to Bardet-Biedl syndrome
The indication is expanded to cover obesity associated with Bardet-Biedl syndrome.
FDA approves Imcivree for POMC deficiency
Imcivree receives U.S. approval for chronic weight management in patients with proopiomelanocortin deficiency.
Biotech investors are tracking Rhythm Pharmaceuticals after Duquesne Family Office disclosed a Q2 2026 stake. Imcivree's 2020 and 2022 FDA approvals for POMC deficiency and Bardet-Biedl syndrome give RYTM an orphan monopoly in a niche GLP-1 leaders can't enter.
Source: finance.yahoo.com · fool.com
Medicare's GLP-1 Bridge pilot, starting July 1, will provide millions of enrollees with access to Wegovy and Zepbound at $50/month, potentially driving blockbuster sales for Novo Nordisk and Eli Lilly while intensifying pricing scrutiny.
Source: wxow.com · wpsdlocal6.com
Eli Lilly's innovative drug pipeline, including treatments for obesity and diabetes, positions it as a leader in biotech, with stock gains of 25% year-to-date signaling strong potential. For biotech professionals, this highlights the impact of clinical successes on market value and future R&D investments. Regulatory contexts like FDA approvals could further accelerate Eli Lilly's dominance in gene therapy and personalized medicine.
Source: fool.com · finance.yahoo.com
Eli Lilly has issued a formal warning regarding "potentially dangerous" impurities discovered in compounded versions of its tirzepatide-based medications, Mounjaro and Zepbound. The company’s internal testing revealed significant safety risks in off-brand formulations, intensifying the ongoing conflict between big pharma and compounding pharmacies.
Zepbound is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
